Bitterroot Bio emerges from stealth with $145M to develop immunotherapies for heart disease
Bitterroot Bio, a biotech company that aims to develop immunotherapies for cardiovascular disease, has announced its emergence from stealth mode and a $145 million series A funding round, the largest-ever investment for a preclinical CVD-focused biotech. The Palo Alto-based company,…